Clinical bottom line
Artificial intelligence (AI) is rapidly advancing as a tool for early detection of lung cancer, primarily through enhanced analysis of imaging modalities such as low-dose computed tomography (LDCT) and positron emission tomography (PET). AI algorithms improve sensitivity and specificity in identifying pulmonary nodules, potentially enabling earlier diagnosis and better patient outcomes. However, challenges remain in integrating AI into clinical workflows, validating algorithms across diverse populations, and addressing cost-effectiveness. Current evidence supports AI as a promising adjunct rather than a standalone diagnostic tool in lung cancer screening (Geppert et al., 2025; Hunter et al., 2022).
What the evidence shows
Geppert et al. (2025) conducted a systematic review and economic evaluation of AI-based software for lung nodule detection on CT scans. They found that AI algorithms generally outperform traditional radiologist interpretation in sensitivity, with variable specificity. Economic models suggest potential cost savings through earlier detection and reduced unnecessary procedures, though real-world implementation data are limited.
Hunter et al. (2022) provide a broad overview of AI’s role in early cancer diagnosis, highlighting lung cancer as a key area where machine learning models facilitate nodule detection, risk stratification, and decision support. They emphasize AI’s ability to analyze large datasets and identify subtle imaging features beyond human perception.
Zukotynski et al. (2022) review AI applications in PET imaging for lung cancer, noting improved lesion characterization and prognostication. Integration of AI with PET/CT may enhance staging accuracy and treatment planning.
Cai et al. (2025) survey medical AI for lung cancer detection, describing advances in deep learning architectures that improve nodule segmentation and malignancy prediction. They discuss challenges including data heterogeneity, algorithm transparency, and regulatory considerations.
Shah et al. (2026) and Khan et al. (2026) further detail emerging AI technologies, including radiomics and multimodal data integration, which promise to refine early detection but require rigorous clinical validation.
Caveats and uncertainty
Most AI studies are retrospective and conducted in controlled research settings, limiting generalizability.
Algorithm performance varies with imaging quality, scanner types, and patient demographics.
False positives remain a concern, potentially leading to overdiagnosis and unnecessary invasive procedures.
Regulatory approval and standardization of AI tools are evolving but not yet uniform.
Economic evaluations rely on modeling assumptions; real-world cost-effectiveness is not fully established.
Clinician acceptance and workflow integration pose practical barriers to adoption.
How this may change practice
AI-assisted imaging interpretation may become a routine adjunct in lung cancer screening programs, improving early detection rates.
Radiologists and pulmonologists will need training to interpret AI outputs and integrate them into clinical decision-making.
AI tools could prioritize high-risk nodules for expedited evaluation, optimizing resource allocation.
Multidisciplinary collaboration will be essential to validate AI algorithms and establish clinical protocols.
Ongoing prospective trials and real-world studies will clarify AI’s impact on patient outcomes and healthcare costs.